世界の内分泌癌治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Neuroendocrine Carcinoma Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5880 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、内分泌癌治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ソマトスタチン類似体、標的療法薬、化学療法薬）、用途別市場規模（病院、クリニック、オンコロジーセンター、外来手術センター）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・内分泌癌治療薬の市場動向 ・企業の競争状況、市場シェア ・内分泌癌治療薬の種類別市場規模と予測2016-2027（ソマトスタチン類似体、標的療法薬、化学療法薬） ・内分泌癌治療薬の用途別市場規模と予測2016-2027（病院、クリニック、オンコロジーセンター、外来手術センター） ・内分泌癌治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・内分泌癌治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・内分泌癌治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・内分泌癌治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・内分泌癌治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、Eli Lilly、CELGENE、Bristol-Myers Squibb、Merck、GlaxoSmithKline、Novartis、Sanofi、Teva Pharmaceuticals Industries） ・結論

Market Analysis and Insights: Global Neuroendocrine Carcinoma Drugs Market
The global Neuroendocrine Carcinoma Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neuroendocrine Carcinoma Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neuroendocrine Carcinoma Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neuroendocrine Carcinoma Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neuroendocrine Carcinoma Drugs market.

Global Neuroendocrine Carcinoma Drugs Scope and Market Size
Neuroendocrine Carcinoma Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neuroendocrine Carcinoma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Somatostatin Analogs
Targeted Therapy Drug
Chemotherapy Drug

Segment by Application
Hospital
Clinics
Oncology Centres
Ambulatory Surgery Centres

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Eli Lilly
CELGENE
Bristol-Myers Squibb
Merck
GlaxoSmithKline
Novartis
Sanofi
Teva Pharmaceuticals Industries

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuroendocrine Carcinoma Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Somatostatin Analogs
1.2.3 Targeted Therapy Drug
1.2.4 Chemotherapy Drug
1.3 Market by Application
1.3.1 Global Neuroendocrine Carcinoma Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Oncology Centres
1.3.5 Ambulatory Surgery Centres
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Neuroendocrine Carcinoma Drugs Market Perspective (2016-2027)
2.2 Neuroendocrine Carcinoma Drugs Growth Trends by Regions
2.2.1 Neuroendocrine Carcinoma Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neuroendocrine Carcinoma Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Neuroendocrine Carcinoma Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Neuroendocrine Carcinoma Drugs Industry Dynamic
2.3.1 Neuroendocrine Carcinoma Drugs Market Trends
2.3.2 Neuroendocrine Carcinoma Drugs Market Drivers
2.3.3 Neuroendocrine Carcinoma Drugs Market Challenges
2.3.4 Neuroendocrine Carcinoma Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Neuroendocrine Carcinoma Drugs Players by Revenue
3.1.1 Global Top Neuroendocrine Carcinoma Drugs Players by Revenue (2016-2021)
3.1.2 Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Neuroendocrine Carcinoma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neuroendocrine Carcinoma Drugs Revenue
3.4 Global Neuroendocrine Carcinoma Drugs Market Concentration Ratio
3.4.1 Global Neuroendocrine Carcinoma Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuroendocrine Carcinoma Drugs Revenue in 2020
3.5 Neuroendocrine Carcinoma Drugs Key Players Head office and Area Served
3.6 Key Players Neuroendocrine Carcinoma Drugs Product Solution and Service
3.7 Date of Enter into Neuroendocrine Carcinoma Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Neuroendocrine Carcinoma Drugs Breakdown Data by Type
4.1 Global Neuroendocrine Carcinoma Drugs Historic Market Size by Type (2016-2021)
4.2 Global Neuroendocrine Carcinoma Drugs Forecasted Market Size by Type (2022-2027)

5 Neuroendocrine Carcinoma Drugs Breakdown Data by Application
5.1 Global Neuroendocrine Carcinoma Drugs Historic Market Size by Application (2016-2021)
5.2 Global Neuroendocrine Carcinoma Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Neuroendocrine Carcinoma Drugs Market Size (2016-2027)
6.2 North America Neuroendocrine Carcinoma Drugs Market Size by Type
6.2.1 North America Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2021)
6.2.2 North America Neuroendocrine Carcinoma Drugs Market Size by Type (2022-2027)
6.2.3 North America Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2027)
6.3 North America Neuroendocrine Carcinoma Drugs Market Size by Application
6.3.1 North America Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2021)
6.3.2 North America Neuroendocrine Carcinoma Drugs Market Size by Application (2022-2027)
6.3.3 North America Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2027)
6.4 North America Neuroendocrine Carcinoma Drugs Market Size by Country
6.4.1 North America Neuroendocrine Carcinoma Drugs Market Size by Country (2016-2021)
6.4.2 North America Neuroendocrine Carcinoma Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Neuroendocrine Carcinoma Drugs Market Size (2016-2027)
7.2 Europe Neuroendocrine Carcinoma Drugs Market Size by Type
7.2.1 Europe Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2021)
7.2.2 Europe Neuroendocrine Carcinoma Drugs Market Size by Type (2022-2027)
7.2.3 Europe Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2027)
7.3 Europe Neuroendocrine Carcinoma Drugs Market Size by Application
7.3.1 Europe Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2021)
7.3.2 Europe Neuroendocrine Carcinoma Drugs Market Size by Application (2022-2027)
7.3.3 Europe Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2027)
7.4 Europe Neuroendocrine Carcinoma Drugs Market Size by Country
7.4.1 Europe Neuroendocrine Carcinoma Drugs Market Size by Country (2016-2021)
7.4.2 Europe Neuroendocrine Carcinoma Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size (2016-2027)
8.2 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Type
8.2.1 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Application
8.3.1 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Region
8.4.1 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Neuroendocrine Carcinoma Drugs Market Size (2016-2027)
9.2 Latin America Neuroendocrine Carcinoma Drugs Market Size by Type
9.2.1 Latin America Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Neuroendocrine Carcinoma Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2027)
9.3 Latin America Neuroendocrine Carcinoma Drugs Market Size by Application
9.3.1 Latin America Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Neuroendocrine Carcinoma Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2027)
9.4 Latin America Neuroendocrine Carcinoma Drugs Market Size by Country
9.4.1 Latin America Neuroendocrine Carcinoma Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Neuroendocrine Carcinoma Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size (2016-2027)
10.2 Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Type
10.2.1 Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Application
10.3.1 Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Country
10.4.1 Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuroendocrine Carcinoma Drugs Introduction
11.1.4 Pfizer Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Neuroendocrine Carcinoma Drugs Introduction
11.2.4 Eli Lilly Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021)
11.2.5 Eli Lilly Recent Development
11.3 CELGENE
11.3.1 CELGENE Company Details
11.3.2 CELGENE Business Overview
11.3.3 CELGENE Neuroendocrine Carcinoma Drugs Introduction
11.3.4 CELGENE Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021)
11.3.5 CELGENE Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Neuroendocrine Carcinoma Drugs Introduction
11.4.4 Bristol-Myers Squibb Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Neuroendocrine Carcinoma Drugs Introduction
11.5.4 Merck Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021)
11.5.5 Merck Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Neuroendocrine Carcinoma Drugs Introduction
11.6.4 GlaxoSmithKline Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021)
11.6.5 GlaxoSmithKline Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Neuroendocrine Carcinoma Drugs Introduction
11.7.4 Novartis Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021)
11.7.5 Novartis Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Details
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Neuroendocrine Carcinoma Drugs Introduction
11.8.4 Sanofi Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021)
11.8.5 Sanofi Recent Development
11.9 Teva Pharmaceuticals Industries
11.9.1 Teva Pharmaceuticals Industries Company Details
11.9.2 Teva Pharmaceuticals Industries Business Overview
11.9.3 Teva Pharmaceuticals Industries Neuroendocrine Carcinoma Drugs Introduction
11.9.4 Teva Pharmaceuticals Industries Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021)
11.9.5 Teva Pharmaceuticals Industries Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Neuroendocrine Carcinoma Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Somatostatin Analogs
Table 3. Key Players of Targeted Therapy Drug
Table 4. Key Players of Chemotherapy Drug
Table 5. Global Neuroendocrine Carcinoma Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Neuroendocrine Carcinoma Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Neuroendocrine Carcinoma Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Neuroendocrine Carcinoma Drugs Market Share by Regions (2016-2021)
Table 9. Global Neuroendocrine Carcinoma Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Neuroendocrine Carcinoma Drugs Market Share by Regions (2022-2027)
Table 11. Neuroendocrine Carcinoma Drugs Market Trends
Table 12. Neuroendocrine Carcinoma Drugs Market Drivers
Table 13. Neuroendocrine Carcinoma Drugs Market Challenges
Table 14. Neuroendocrine Carcinoma Drugs Market Restraints
Table 15. Global Neuroendocrine Carcinoma Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Neuroendocrine Carcinoma Drugs Market Share by Players (2016-2021)
Table 17. Global Top Neuroendocrine Carcinoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Carcinoma Drugs as of 2020)
Table 18. Ranking of Global Top Neuroendocrine Carcinoma Drugs Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Neuroendocrine Carcinoma Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Neuroendocrine Carcinoma Drugs Product Solution and Service
Table 22. Date of Enter into Neuroendocrine Carcinoma Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Type (2016-2021)
Table 26. Global Neuroendocrine Carcinoma Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Neuroendocrine Carcinoma Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Application (2016-2021)
Table 30. Global Neuroendocrine Carcinoma Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Neuroendocrine Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Neuroendocrine Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Neuroendocrine Carcinoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Neuroendocrine Carcinoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Neuroendocrine Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Neuroendocrine Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Neuroendocrine Carcinoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Neuroendocrine Carcinoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Neuroendocrine Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Neuroendocrine Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Neuroendocrine Carcinoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Neuroendocrine Carcinoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 62. Pfizer Company Details
Table 63. Pfizer Business Overview
Table 64. Pfizer Neuroendocrine Carcinoma Drugs Product
Table 65. Pfizer Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 66. Pfizer Recent Development
Table 67. Eli Lilly Company Details
Table 68. Eli Lilly Business Overview
Table 69. Eli Lilly Neuroendocrine Carcinoma Drugs Product
Table 70. Eli Lilly Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 71. Eli Lilly Recent Development
Table 72. CELGENE Company Details
Table 73. CELGENE Business Overview
Table 74. CELGENE Neuroendocrine Carcinoma Drugs Product
Table 75. CELGENE Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 76. CELGENE Recent Development
Table 77. Bristol-Myers Squibb Company Details
Table 78. Bristol-Myers Squibb Business Overview
Table 79. Bristol-Myers Squibb Neuroendocrine Carcinoma Drugs Product
Table 80. Bristol-Myers Squibb Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 81. Bristol-Myers Squibb Recent Development
Table 82. Merck Company Details
Table 83. Merck Business Overview
Table 84. Merck Neuroendocrine Carcinoma Drugs Product
Table 85. Merck Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 86. Merck Recent Development
Table 87. GlaxoSmithKline Company Details
Table 88. GlaxoSmithKline Business Overview
Table 89. GlaxoSmithKline Neuroendocrine Carcinoma Drugs Product
Table 90. GlaxoSmithKline Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 91. GlaxoSmithKline Recent Development
Table 92. Novartis Company Details
Table 93. Novartis Business Overview
Table 94. Novartis Neuroendocrine Carcinoma Drugs Product
Table 95. Novartis Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 96. Novartis Recent Development
Table 97. Sanofi Company Details
Table 98. Sanofi Business Overview
Table 99. Sanofi Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 100. Sanofi Recent Development
Table 101. Teva Pharmaceuticals Industries Company Details
Table 102. Teva Pharmaceuticals Industries Business Overview
Table 103. Teva Pharmaceuticals Industries Neuroendocrine Carcinoma Drugs Product
Table 104. Teva Pharmaceuticals Industries Revenue in Neuroendocrine Carcinoma Drugs Business (2016-2021) & (US$ Million)
Table 105. Teva Pharmaceuticals Industries Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuroendocrine Carcinoma Drugs Market Share by Type: 2020 VS 2027
Figure 2. Somatostatin Analogs Features
Figure 3. Targeted Therapy Drug Features
Figure 4. Chemotherapy Drug Features
Figure 5. Global Neuroendocrine Carcinoma Drugs Market Share by Application: 2020 VS 2027
Figure 6. Hospital Case Studies
Figure 7. Clinics Case Studies
Figure 8. Oncology Centres Case Studies
Figure 9. Ambulatory Surgery Centres Case Studies
Figure 10. Neuroendocrine Carcinoma Drugs Report Years Considered
Figure 11. Global Neuroendocrine Carcinoma Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Neuroendocrine Carcinoma Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Neuroendocrine Carcinoma Drugs Market Share by Regions: 2020 VS 2027
Figure 14. Global Neuroendocrine Carcinoma Drugs Market Share by Regions (2022-2027)
Figure 15. Global Neuroendocrine Carcinoma Drugs Market Share by Players in 2020
Figure 16. Global Top Neuroendocrine Carcinoma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Carcinoma Drugs as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Neuroendocrine Carcinoma Drugs Revenue in 2020
Figure 18. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Type (2016-2021)
Figure 19. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Type (2022-2027)
Figure 20. North America Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Neuroendocrine Carcinoma Drugs Market Share by Type (2016-2027)
Figure 22. North America Neuroendocrine Carcinoma Drugs Market Share by Application (2016-2027)
Figure 23. North America Neuroendocrine Carcinoma Drugs Market Share by Country (2016-2027)
Figure 24. United States Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Neuroendocrine Carcinoma Drugs Market Share by Type (2016-2027)
Figure 28. Europe Neuroendocrine Carcinoma Drugs Market Share by Application (2016-2027)
Figure 29. Europe Neuroendocrine Carcinoma Drugs Market Share by Country (2016-2027)
Figure 30. Germany Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Share by Region (2016-2027)
Figure 40. China Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Neuroendocrine Carcinoma Drugs Market Share by Type (2016-2027)
Figure 48. Latin America Neuroendocrine Carcinoma Drugs Market Share by Application (2016-2027)
Figure 49. Latin America Neuroendocrine Carcinoma Drugs Market Share by Country (2016-2027)
Figure 50. Mexico Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Neuroendocrine Carcinoma Drugs Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Neuroendocrine Carcinoma Drugs Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Neuroendocrine Carcinoma Drugs Market Share by Country (2016-2027)
Figure 56. Turkey Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Neuroendocrine Carcinoma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Pfizer Revenue Growth Rate in Neuroendocrine Carcinoma Drugs Business (2016-2021)
Figure 60. Eli Lilly Revenue Growth Rate in Neuroendocrine Carcinoma Drugs Business (2016-2021)
Figure 61. CELGENE Revenue Growth Rate in Neuroendocrine Carcinoma Drugs Business (2016-2021)
Figure 62. Bristol-Myers Squibb Revenue Growth Rate in Neuroendocrine Carcinoma Drugs Business (2016-2021)
Figure 63. Merck Revenue Growth Rate in Neuroendocrine Carcinoma Drugs Business (2016-2021)
Figure 64. GlaxoSmithKline Revenue Growth Rate in Neuroendocrine Carcinoma Drugs Business (2016-2021)
Figure 65. Novartis Revenue Growth Rate in Neuroendocrine Carcinoma Drugs Business (2016-2021)
Figure 66. Sanofi Revenue Growth Rate in Neuroendocrine Carcinoma Drugs Business (2016-2021)
Figure 67. Teva Pharmaceuticals Industries Revenue Growth Rate in Neuroendocrine Carcinoma Drugs Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---